EULAR recommendations for the management of familial Mediterranean fever
- 22 January 2016
- journal article
- review article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 75 (4), 644-651
- https://doi.org/10.1136/annrheumdis-2015-208690
Abstract
Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, but many rheumatologists are not well acquainted with its management. The objective of this report is to produce evidence-based recommendations to guide rheumatologists and other health professionals in the treatment and follow-up of patients with FMF. A multidisciplinary panel, including rheumatologists, internists, paediatricians, a nurse, a methodologist and a patient representative, was assembled. Panellists came from the Eastern Mediterranean area, Europe and North America. A preliminary systematic literature search on the pharmacological treatment of FMF was performed following which the expert group convened to define aims, scope and users of the guidelines and established the need for additional reviews on controversial topics. In a second meeting, recommendations were discussed and refined in light of available evidence. Finally, agreement with the recommendations was obtained from a larger group of experts through a Delphi survey. The level of evidence (LoE) and grade of recommendation (GR) were then incorporated. The final document comprises 18 recommendations, each presented with its degree of agreement (0–10), LoE, GR and rationale. The degree of agreement was greater than 7/10 in all instances. The more controversial statements were those related to follow-up and dose change, for which supporting evidence is limited. A set of widely accepted recommendations for the treatment and monitoring of FMF is presented, supported by the best available evidence and expert opinion. It is believed that these recommendations will be useful in guiding physicians in the care of patients with FMF.Keywords
This publication has 62 references indexed in Scilit:
- 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendationsAnnals Of The Rheumatic Diseases, 2014
- Evidence-based recommendations for the practical management of Familial Mediterranean FeverSeminars in Arthritis and Rheumatism, 2013
- Pharmacokinetics and Colchicine in Pediatric and Adult Patients with Familial Mediterranean FeverInternational Journal of Immunopathology and Pharmacology, 2012
- Familial Mediterranean FeverMedicine, 2012
- Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus StatementPEDIATRICS, 2007
- Diagnostic and treatment concerns in familial Mediterranean feverBest Practice & Research Clinical Rheumatology, 2000
- Familial Mediterranean fever in children: the expanded clinical profileQJM: An International Journal of Medicine, 1999
- COLCHICINE TREATMENT OF AA AMYLOIDOSIS OF FAMILIAL MEDITERRANEAN FEVERArthritis & Rheumatism, 1994
- Colchicine Prevents Kidney Transplant Amyloidosis in Familial Mediterranean FeverNephron, 1992
- Colchicine in the Prevention and Treatment of the Amyloidosis of Familial Mediterranean FeverThe New England Journal of Medicine, 1986